Related Experiment Video

Updated: Mar 1, 2026

Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice
09:29

Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice

Published on: June 11, 2020

3.8K

Phenobarbital and midazolam increase neonatal seizure-associated neuronal injury

Daniel Torolira1, Lucie Suchomelova1, Claude G Wasterlain1,2,3

  • 1Epilepsy Research Laboratory (151), Veterans Affairs Greater Los Angeles Healthcare System.

Annals of Neurology
|May 31, 2017
PubMed

Insights

Standard seizure medications like phenobarbital and midazolam may worsen brain injury in neonatal seizures. Further research is needed to explore the harmful effects of these gamma-aminobutyric acid (GABA) drugs on immature brains.

Area of Science:

  • Neuroscience
  • Neonatal Neurology
  • Pharmacology

Background:

  • Neonatal seizures, including status epilepticus, are common and linked to brain damage and developmental issues.
  • Current treatments, such as gamma-aminobutyric acid (GABA) drugs, can paradoxically excite the neonatal brain, potentially exacerbating seizures and injury.

Purpose of the Study:

  • To investigate the impact of GABAergic drugs on neuronal injury in a neonatal rat model of status epilepticus.
  • To evaluate the efficacy and safety of standard anti-seizure medications in the context of immature brain development.

Main Methods:

  • Utilized a validated rat pup model of status epilepticus at postnatal day 7.
  • Administered GABAA agonists, phenobarbital and midazolam, to assess their effects on neuronal injury.
  • Quantified seizure-associated neuronal damage across multiple brain regions.

Main Results:

  • Phenobarbital and midazolam significantly increased neuronal injury in various brain regions.
  • The study demonstrated a detrimental effect of standard GABAergic treatments on seizure-induced brain damage in neonates.
  • Widespread neuronal injury was observed in the established neonatal status epilepticus model.

Conclusions:

  • GABAergic drugs, commonly used for neonatal seizures, may exacerbate excitotoxic neuronal injury in the developing brain.
  • Findings highlight the need for further investigation into the adverse effects of GABAergic medications on neonatal brain injury.
  • Alternative or adjunctive therapeutic strategies may be required for managing neonatal status epilepticus to prevent long-term developmental consequences.

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

35.2K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.4K

Related Concept Videos

Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.5K
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
824
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
867